Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sul- famethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice
- Autores: Antunes F, Cardoso F, Cushion MT, de Sousa B, Esteves F, Lobo ML, Matos O
- Ano de Publicação: 2013
- Journal: PLoS One
- Link: http://www.ncbi.nlm.nih.gov/pubmed/23940606
Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for PcP.